Beginner-friendly– category –

This article is the second half of the Morningglorysciences Summer Beginner Series Grand Summary. In Part 1, we reviewed anti-obesity drugs, ADCs, and In vivo CAR-T cell therapy, comparing their strengths and shared challenges. Here in P...

This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. We revisit three major therapeutic modalities—anti-obesity drugs, antibody-drug conjugates (ADCs), and In vivo CAR-T cell therapy—highlighti...

This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on “In vivo CAR-T.” Previous articles covered the basics, leading researchers and companies, technical challenges, and global partnerships. Here...

This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on Antibody-Drug Conjugates (ADCs). Throughout the series, we introduced the basics, design principles, historical improvements, and clinical ap...

This article is a comprehensive summary of our Morningglorysciences Summer Beginner Series on anti-obesity drugs. Throughout the series, we explored the history of obesity treatments, the clinical progress of GLP-1 receptor agonists, and...

In this final deep-dive of our beginner-friendly bispecific antibody series, we explore the historical trajectory of bispecific antibody (BsAb) technology. From early-stage instability to today’s modular, multifunctional platforms, the e...

In this final volume, we summarize the latest developments in bispecific antibody drug R&D by leading biotech and pharma companies, as well as major approvals over the past year in the US and EU. We also highlight key trends and nota...

Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significantly depending on the structural modality. This article explains in simple terms how differences in modalities—such as IgG-based, non-IgG, a...

In this third installment of our Beginner-Friendly Bispecific Antibody Drug series, we delve into the crucial question: “Which targets should be selected?” Target selection is a core strategic decision in bispecific antibody development,...

In this second installment of our series on bispecific antibody drugs, we delve into the diverse structural formats that define the field. From tandem scFvs to full-length IgG-like structures, we examine how these formats affect function...

Introduction: Why Are Bispecific Antibody Drugs Gaining Attention? In recent years, bispecific antibody drugs (BsAbs) have garnered increasing attention in the treatment of cancer, autoimmune diseases, and infectious diseases. By binding...

Global Strategies Shaping the Future of in vivo CAR-T Development Throughout this series, we have explored the cutting-edge developments of in vivo CAR-T therapy in an accessible way for beginners. In this final installment, we will exam...

Key Figures Shaping the Future of in vivo CAR-T This series aims to provide a clear and accessible overview of the latest advancements in in vivo CAR-T therapies, especially for beginners. In Part 7, we focus on the global researchers, e...

In vivo CAR-T therapy has rapidly emerged as a promising next-generation cancer treatment. However, realizing its full potential requires overcoming several hurdles: targeting only the desired cells, ensuring safety, and maintaining sust...

In previous installments, we've explored the fundamentals of CAR-T, the features of the in vivo model, gene delivery strategies, target antigens, and intracellular signaling. In this fifth edition, we shift our focus to clinical applicat...

For in vivo CAR-T cells to attack cancer persistently and effectively, the structure of the CAR itself is critical. In particular, the design of co-stimulatory molecules and intracellular signaling domains directly impacts the treatment'...

In this third installment of our introductory series on in vivo CAR-T, we focus on a vital component for realizing safe and effective therapy: the design of CAR expression. We explore how “smart control” of CAR expression—targeting tumor...

In the first installment of our series, we introduced the revolutionary CAR-T cell therapy through the moving story of Emily Whitehead. This time, we take a deep dive into the underlying technologies that make “in vivo CAR-T” possible. F...

CAR-T cell therapy has emerged as a groundbreaking treatment that specifically targets cancer cells. Among its forms, the “in vivo type” CAR-T—where the therapeutic process happens inside the body—is gaining attention as a next-generatio...

Over the past few years, the landscape of Antibody-Drug Conjugates (ADCs) has undergone a dramatic transformation, shifting from a niche therapeutic approach to a central pillar of oncology innovation. This bonus chapter highlights recen...